Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.
about
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelinesEpstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic targetReal-time PCR in clinical microbiology: applications for routine laboratory testing.Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients.Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis.High fatality rate of Epstein-Barr virus-associated lymphoproliferative disorder occurring after bone marrow transplantation with rabbit antithymocyte globulin conditioning regimens.Detection of Herpesviridae in whole blood by multiplex PCR DNA-based microarray analysis after hematopoietic stem cell transplantation.Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantationLong-term outcome for immune suppression and immune related lymphoproliferative disorder: prospective data from the United Kingdom Children's Leukaemia and Cancer Group registry 1994-2004.Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challengeRecovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases).Epstein-barr virus related lymphoproliferations after stem cell transplantation.Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program.Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.Prevention and treatment of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of bone marrow and solid organ transplants.Molecular diagnosis of Epstein-Barr virus.Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults?Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemiaRituximab for steroid-refractory chronic graft-versus-host disease.Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantationCellular immunotherapy for viral infection after HSC transplantation.Significance of Epstein-Barr virus (EBV) load and interleukin-10 in post-transplant lymphoproliferative disorders.Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO).Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development.Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation eventVariable EBV DNA load distributions and heterogeneous EBV mRNA expression patterns in the circulation of solid organ versus stem cell transplant recipients.Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning.Infectious complications following unrelated cord blood transplantation.Secondary Malignant Neoplasms Following Haematopoietic Stem Cell Transplantation in ChildhoodImmune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients.Laboratory assays for Epstein-Barr virus-related disease.Comparison of the Abbott Realtime HIV-1 and HCV viral load assays with commercial competitor assays.Clinical characteristics and outcomes of posttransplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation in Korea.How I treat EBV lymphoproliferation.Quantitative nucleic acid amplification methods and their implications in clinical virology.Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.
P2860
Q26745838-8797B234-2E6A-41F4-879D-0C2F4C15F444Q26822550-C44BD627-5CC0-4D65-B855-8FE7703C9C41Q27472851-31D38479-7FC4-433D-987B-ADD9278504CCQ33634455-CFC902E9-BCF7-432A-B905-8C6506C20811Q33695997-15502EC2-1D5E-418F-B3CF-900324E6A891Q33732489-53DC9EC7-A182-487B-BFC5-CBB05BB62AE7Q33884942-5CE3529A-566A-4D9D-832B-A35F899282C5Q33900083-C432E989-D3DB-4037-970A-E6F03507C66CQ33962254-5156B7F4-663F-486B-85D5-8924A418F1FCQ34056575-20984F0D-FBB6-428A-990E-4D1FDFC681EFQ34058118-B12B5A34-AF4D-4396-8797-8CCB9D974516Q34208618-0A09EC8D-92CD-45C5-BDE3-7858FBE5DEEBQ34549457-33BBEEA3-D0D6-4700-80C1-393EB3296869Q34573919-D1E84B86-04A1-4073-B4C3-A3A58DB792B9Q34622755-0E720339-C183-463A-BD01-5DAC1ED62400Q35001143-C1D55E7B-3915-4692-9C48-C286DC549855Q35045293-F009F099-8382-4F25-8668-7F008E8E7330Q35237511-8038FA3D-61CE-404B-BABA-D7B32B6A0CBCQ35751004-15E5477B-6DB0-4477-9AD4-34A9A0A3F857Q35848933-92752A81-0E32-4E93-9DC5-04CEEF27AD90Q35849338-8CCFE41C-DDFF-4CD6-80C3-4775763F1C65Q35998792-EBDF86AF-5823-4762-820A-804A5BC8C404Q36272592-BEE6A503-ACC6-4D73-BBA4-08C3358A12D0Q36367268-E1A642DF-F88C-49D7-925D-4922480F65ADQ36389306-65334499-96E7-4D39-8C41-08EFF0F917E8Q36435819-5DF74049-CF92-4B4A-9B19-EB9F26E2BC5CQ36519976-7BC19651-9615-4F9B-8599-C97E9BD90A46Q36537637-25C1E0D3-6BF4-4BAA-947F-698781FDB91FQ36556729-17456DB7-52C3-47C0-BA79-2FC3FC1E9B21Q36746437-B29E5A61-84BA-44D4-94CE-589D74F5B7DEQ36800530-3ED1079C-B0EC-4764-9D83-1F2082640E7DQ37055896-58ED659B-CCD6-4AB1-A7CC-AEA2A2CBB48FQ37152749-B024E5B4-ED11-487D-986E-36CB063A9FA3Q37192117-EB2E8D6B-884B-4C38-9E37-4055A9BDEBFCQ37206232-C4119891-DA91-4B96-AA06-D989500DE8EFQ37323929-6A870E59-2F6F-4EB2-A309-67B52E41B80CQ37414678-1B8E1942-9B88-4DBE-9FDF-AA7E19FA860AQ37668438-30C1EFC2-8CD7-49C2-AEAF-F4ABACC4861EQ37726624-BFB32CCE-AD88-4ADD-8191-4A4A8DEB91CBQ37793222-79E0EAF1-FE36-40C1-BC8B-72589AE39499
P2860
Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Prevention of Epstein-Barr vir ...... eic stem cell transplantation.
@ast
Prevention of Epstein-Barr vir ...... eic stem cell transplantation.
@en
type
label
Prevention of Epstein-Barr vir ...... eic stem cell transplantation.
@ast
Prevention of Epstein-Barr vir ...... eic stem cell transplantation.
@en
prefLabel
Prevention of Epstein-Barr vir ...... eic stem cell transplantation.
@ast
Prevention of Epstein-Barr vir ...... eic stem cell transplantation.
@en
P2093
P1433
P1476
Prevention of Epstein-Barr vir ...... eic stem cell transplantation.
@en
P2093
Bronno van der Holt
Ellen Meijer
Hubert G M Niesters
Jan J Cornelissen
Jan Willem Gratama
Joost W J van Esser
Leo F Verdonck
P304
P356
10.1182/BLOOD.V99.12.4364
P407
P577
2002-06-01T00:00:00Z